Mexico Nixes Pfizer-Nestlé Deal, Impax Partners with Perrigo: Healthcare Biz Review

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Nestle’s (NSRGY.PK) proposed acquisition of Pfizer’s (NYSE:PFE) baby foods division in Mexico has been nixed by regulators there as it would become too large in terms of market share in that country. Prior to this, Nestlé topped Danone’s (DANOY.PK) offer of nearly $12 billion for the unit. However, it has been reckoned that should the deal with Pfizer goes through, somewhere between 71 and 88 per cent of the sector would be controlled by Nestlé.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

In a Wednesday press release, Impax Laboratories (NASDAQ:IPXL) said that it will partner with Perrigo Company (NASDAQ:PRGO) on the development, manufacturing and commercialization of an extended topical generic drug product possessing first-to-market potential. The product was not identified  and the arrangement’s terms were not reported.

Don’t Miss: Here’s The Shocking Secret Teavana Kept From Starbucks.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business